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 Abstract 
 Background/Aims: To investigate the differences in brain glucose consumption between pa-
tients with early onset of Alzheimer’s disease (EOAD, aged  ≤ 65 years) and patients with late 
onset of Alzheimer’s disease (LOAD, aged >65 years).  Methods: Differences in brain glucose 
consumption between the groups have been evaluated by means of Statistical Parametric 
Mapping version 8, with the use of age, sex, Mini-Mental State Examination and cerebrospinal 
fluid values of Aβ 1–42 , phosphorylated Tau and total Tau as covariates in the comparison be-
tween EOAD and LOAD.  Results: As compared to LOAD, EOAD patients showed a significant 
decrease in glucose consumption in a wide portion of the left parietal lobe (BA7, BA31 and 
BA40). No significant differences were obtained when subtracting the EOAD from the LOAD 
group.  Conclusions: The results of our study show that patients with EOAD show a different 
metabolic pattern as compared to those with LOAD that mainly involves the left parietal lobe. 
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 Introduction 
 Alzheimer’s disease (AD) is a neurodegenerative disorder responsible for progressive 
cognitive decline and dementia  [1, 2] . Although it is generally defined as an age-related 
disorder, cases with early onset are described  [3, 4] . These cases represent the early-onset 
AD (EOAD) group and are defined by a clinical onset of AD before the age of 65 years. EOAD 
cases are both familial and sporadic and represent about 10% of all AD cases. EOAD can 
manifest clinically with nonamnestic symptoms in 25–65% of cases, presenting with language 
deficits, apraxia and visuospatial functional deficits  [5, 6] . Such a presentation often overlaps 
with frontotemporal degeneration syndromes or with psychiatric conditions, causing great 
diagnostic delay  [7, 8] . Although neuropathological studies showed that EOAD and LOAD 
have the same features and represent a continuum of the same pathological process, differ-
ences between EOAD and LOAD are reported  [9, 10] . Indeed, EOAD patients often present (in 
about half of the cases described in the literature) with atypical neuropsychological symptoms 
and have an atypical MRI and  18 F-FDG PET imaging pattern, with cortical thickness atrophy 
and hypometabolism, respectively, of the mesial temporal and parietal lobes (i.e. precuneus, 
lateral parietal and occipital brain regions) with relative hippocampal sparing, with respect 
to LOAD, where hippocampi are more involved; in addition, EOAD patients tend to have a 
more aggressive rate of progression with a shorter duration of the disease than LOAD patients 
 [11–13] . These observations led us to suppose that EOAD might represent a definite clinico-
pathological entity, characterized by distinct pathophysiological mechanisms and patho-
logical burden responsible for a faster decline as well as for atypical presentation. Several 
recent studies have investigated cerebrospinal fluid (CSF) biomarkers of EOAD, focusing on 
atypical presentations, with controversial results  [14] . Although differences do not reach 
statistical significance, EOAD individuals often show lower CSF Aβ 42 and very high total Tau 
(t-Tau) levels, features that are compatible with faster cognitive decline in AD. [ 11 C]-labeled 
Pittsburgh compound B studies showed greater Aβ accumulation in posterior cortical areas, 
indicating a possible vulnerability in these individuals for these regions  [15, 16] . However, 
most of the available data uniquely describe EOAD with atypical presentation, and the radio-
logical and laboratory findings presented in the literature often reflect the asymmetric and 
focal localization features of EOAD. Data on the amnestic presentation of EOAD are, to our 
knowledge, not available. Here, we present a CSF analysis and an  18 F-FDG PET study of a 
subgroup of EOAD patients with a typical amnestic presentation and compare them with a 
group of LOAD patients with an amnestic presentation. 
 Materials and Methods 
 Patients 
 We examined a total of 84 patients with a diagnosis of probable AD according to the 
NINCDS-ADRDA criteria  [17] . The mean age (±SD) of the patients was 69 (±7) years. Based 
on the age at onset, the patients could be divided into an EOAD ( ≤ 65 years of age) and an 
LOAD (>65 years of age) group. The EOAD group consisted of 23 patients, with a mean age 
of 64 (±2) years, while 65 patients were in the LOAD group, with a mean age of 76 (±3) years. 
All patients underwent a complete clinical investigation, including a medical history, neuro-
logical examination, Mini-Mental State Examination (MMSE), a complete blood screening 
(including routine examinations, thyroid hormones, level of vitamin B 12 ), a neuropsycho-
logical examination  [18] , a complete neuropsychiatric evaluation and neuroimaging 
consisting of magnetic resonance imaging (1.5-tesla MRI). Exclusion criteria were the 
following: patients with isolated deficits and/or unmodified MMSE ( ≥ 25/30) on revisit (6, 
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12 and 18 months of follow-up) and patients with clinically manifest acute stroke in the 
previous 6 months showing a Hachinski scale score >4 and radiological evidence of subcor-
tical lesions. None of the patients revealed pyramidal and/or extrapyramidal signs at the 
neurological examination. At the time of enrolment, in the 30 days before participating in 
this study, none of the patients had been treated with drugs that might have modulated 
cerebral cortex excitability, such as antidepressants, or any other neuroactive drugs (i.e. 
benzodiazepines, antiepileptic drugs or neuroleptics), and they had not been treated with 
cholinesterase inhibitors. 
 The study was performed according to the Declaration of Helsinki and was approved by 
the Ethics Committee of the Tor Vergata University in Rome. All AD patients showed a 
cognitive profile consistent with mild dementia, as assessed by a neuropsychological evalu-
ation including the MMSE and a standardized neuropsychological battery  [19] . On the MMSE, 
AD patients scored a mean of 18.5 ± 6.4, and the Clinical Dementia Rating score was 1.3 ± 1.21. 
A general overview of the AD population examined is provided in  table 1 . All participants or 
their legal guardians gave their written informed consent after receiving extensive infor-
mation on the study. The Local Ethics Committee approved the study procedures. 
 Cognitive Evaluation 
 At the time of enrollment, all recruited patients were administered a neuropsychological 
battery ( table 2 ) including the following cognitive domains: general cognitive efficiency 
(MMSE)  [20] ; verbal episodic long-term memory (Rey Auditory Verbal Learning Test, long-
term memory, 15-word list immediate and 15-min delayed recall)  [21] ; visuospatial abilities 
and visuospatial episodic long-term memory (Rey Complex Figure Test, copy and 10-min 
delayed recall)  [22] ; executive functions (Phonological Word Fluency Test)  [19] , and analogic 
reasoning (Raven’s Colored Progressive Matrices)  [19] . For all tests employed, we used the 
 Table 1.  Outline of the AD population examined
Population (n = 84) U65 (n = 23) O65 (n = 61) p value
Mean age ± SD, years 69 ± 7 60.5 ± 2 76 ± 3 <0.01
MMSE score 18.52 ± 6.481 18.18 ± 7.292 18.65 ± 6.209 0.5466
t-Tau, pg/ml 678.8 ± 322.5 768.9 ± 363 644.9 ± 302.2 0.1118
p-Tau, pg/ml 81.29 ± 47.19 82.70 ± 34.56 80.75 ± 51.40 0.2831
Aβ1 – 42, pg/ml 321.2 ± 127. 1 300.5 ± 133 329.0 ± 125 0.4281
 Table 2. Neuropsychological evaluation of the EOAD and LOAD groups
EOAD LOAD p
MMSE score 18.9 ± 1.3 19.2 ± 0.7 n.s.
Rey Auditory Verbal Learning Test, immediate recall 15.9 ± 1.6 22.5 ± 0.9 0.0032
Rey Auditory Verbal Learning Test, delayed recall 1.57 ± 0.4 2.19 ± 0.3 n.s.
Rey Complex Figure Test, copy 16.35 ± 2.3 17.52 ± 1.3 n.s.
Rey Complex Figure Test, delayed recall 4.34 ± 1.1 7.45 ± 0.7 0.05
Raven’s Colored Progressive Matrices 15.8 ± 1.4 20.27 ± 0.7 n.s.
Phonological Word Fluency Test 19.47 ± 2.4 22.15 ± 1.3 n.s.
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Italian normative data for both score adjustment (gender, age and education) and to define 
cutoff scores of normality, determined as the lower limit of the 95% tolerance interval. For 
each test, normative data are reported in the corresponding references.
 CSF Sampling 
 In our study, we performed lumbar puncture and CSF sampling to improve the diag-
nostic accuracy in the AD patients. The first 12 ml of CSF were collected in a polypropylene 
tube and directly transported to the local laboratory for centrifugation at 2,000  g at +4 ° C for 
10 min. The supernatant was pipetted off, gently stirred and mixed to avoid potential gradient 
effects, and aliquoted in 1-ml portions in polypropylene tubes that were stored at –80  °  C 
pending biochemical analyses, without being thawed and re-frozen. In the AD patients, CSF 
t-Tau and phosphorylated Tau (p-Tau, Thr181) concentrations were determined using a 
sandwich ELISA (Innotest ® hTAU-Ag, Innogenetics, Gent, Belgium). CSF Aβ 1–42 levels were 
determined using a sandwich ELISA [Innotest β-amyloid(1–42), Innogenetics] specifically 
constructed to measure Aβ containing both the first and 42nd amino acid, as previously 
described  [23] .
 Control Group 
 Fifty-eight chemotherapy-naïve subjects (males, 33; females, 25; mean age, 67 ± 9 years) 
undergoing an  18 F-FDG PET/CT and found to be completely negative for various diseases 
were enrolled in the study and served as the control group (CG), as proposed in other previous 
studies  [24] . Of them, 22 (males, 10; females, 12) were under 65 years old (U65) and 36 
(females, 11; males, 25) were over 65 years old (O65). Part of them has already been considered 
in another study published by our group  [25] . Before their inclusion in our study, all of them 
had previously been evaluated for the absence of clinical signs of AD by an experienced 
neurologist (A.M.), and the MRI, performed 7 ± 2 days before PET/CT examination, was 
negative for brain injury in all of them.
 PET/CT Scanning 
 The PET/CT system Discovery VCT (GE Medical Systems, Knoxville, Tenn., USA) was used 
to assess  18 F-FDG brain distribution in all patients by means of a 3-dimensional mode standard 
technique in a 256 × 256 matrix. Reconstruction was performed using the 3-dimensional 
reconstruction method of ordered subset expectation maximization with 20 subsets and with 
4 iterations. The system combines a high-speed ultra 16-detector row (912 detectors per 
row) CT unit and a PET scanner with 13,440 bismuth germanate crystals in 24 rings (axial 
full width at half maximum 1-cm radius, 5.2 mm in the 3-dimensional mode, axial field of view 
157 mm). A low-ampere CT scan of the head for attenuation correction (40 mA; 120 Kv) was 
performed before PET image acquisition. 
 All the subjects had fasted for at least 6 h before intravenous injection of  18 F-FDG; the 
dose range administered was 185–210 MBq. After the injection, all the patients lay down in 
a noiseless and semi-darkened room with their eyes open and without any artificial stimu-
lation. PET/CT acquisition started 30 min after  18 F-FDG injection. 
 Patients and controls with diabetes, psychiatric disorders, a history of oncologic disease, 
HIV, epilepsy and surgery, radiation or trauma to the brain were excluded from the study. 
Patients were not taking any medications. Moreover, we excluded from our study all the 
patients treated with drugs that could interfere with  18 F-FDG uptake and distribution in the 
brain  [26] .
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 Statistical Analysis 
 We calculated the mean and SD for age, p-Tau, t-Tau, Aβ 1–42 amyloid peptide and MMSE. 
In order to make sure that the values of the main clinical and CSF parameter examined had a 
Gaussian distribution, D’Agostino’s K squared normality test was applied (where the null 
hypothesis means that the data are normally distributed). Differences in clinical and CSF 
parameters between EOAD and LOAD and CG subjects were evaluated by means of the Mann-
Whitney U test. Differences in brain  18 F-FDG uptake were analyzed using Statistical Para-
metric Mapping (SPM8, Wellcome Department of Cognitive Neurology, London, UK) imple-
mented in MATLAB 2012b (Mathworks, Natick, Mass., USA). PET data were subjected to 
affine and nonlinear spatial normalization into the Montreal Neurological Institute space. The 
spatially normalized set of images was then smoothed with an 8-mm isotropic Gaussian filter 
to blur individual variations in gyral anatomy and to increase the signal-to-noise ratio. Images 
were globally normalized using proportional scaling to remove confounding effects to global 
cerebral glucose metabolism changes, with a threshold masking of 0.8. The resulting statis-
tical parametric maps (SPM{t}) were transformed into a normal distribution (SPM{z}) unit. 
Correction of SPM coordinates to match the Talairach coordinates was achieved by the 
subroutine implemented by Matthew Brett (http://www.mrc-cbu.cam.ac.uk/Imaging). 
Brodmann areas (BAs) were then identified at a range of 0–3 mm from the corrected Talairach 
coordinates of the SPM output isocenters, after having imported them from the Talairach 
client (http://www.talairach.org/index.html). Thresholds  ≤ 0.001 corrected at cluster level 
were accepted as significant. Only those clusters containing more than 125 (5 × 5 × 5 voxels, 
i.e. 11 × 11 × 11 mm) contiguous voxels were accepted as significant, based on the calculation 
of the partial volume effect resulting from the spatial resolution of the PET camera (about 
double the full width at half maximum). The following voxel-based comparisons were assessed 
for AD patients: LOAD versus EOAD and vice versa. As far as the CG is concerned, the following 
voxel-based comparisons were assessed: O65 versus U65 and vice versa. In the comparison 
between AD and CG subjects, the following voxel-based comparisons were assessed: LOAD 
versus O65 and vice versa, and EOAD versus U65 and vice versa. All the comparisons were 
performed using a ‘two-sample t test’ design model. 
 In the SPM maps, we searched the brain areas with a significant correlation using a statis-
tical threshold of p = 0.001, familywise error corrected for the problem of multiple compar-
isons, with an extent threshold of 100 voxels.
 With the exception of the comparisons in which a CG was used (in which CSF was not 
tested), age, sex, MMSE, t-Tau, p-Tau and Aβ 1–42 were used as covariates in the SPM analyses.
 Results 
 The values for MMSE, age, p-Tau, t-Tau and Aβ 1–42 amyloid peptide were not normally 
distributed (p < 0.001). We did not find statistically significant differences when comparing 
age, p-Tau, t-Tau, Aβ 1–42 amyloid peptide and MMSE in EOAD versus LOAD patients. In 
particular, the results of the comparisons were: p > 0.9 for MMSE; p = 0.226 for t-Tau; p = 
0.284 for p-Tau, and p = 0.429 for Aβ 1–42 amyloid peptide ( fig. 1 ).
 AD Patients (O65 vs. U65 and vice versa) 
 As compared to LOAD patients, EOAD patients showed a significant decrease in glucose 
consumption in a wide portion of the left parietal lobe (BA7, BA31 and BA40). No significant 
differences were obtained when subtracting the EOAD group from the LOAD group (no 
increased glucose consumption in the LOAD as compared to the EOAD group). Detailed results 
are provided in  table 3 and  figure 2 . 
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 Fig. 1. Box plots of the data in  table 1 showing no significant differences in t-Tau ( a ), p-Tau ( b ) and Aβ 1–42 
amyloid peptide ( c ) levels in CSF in LOAD versus EOAD patients.  
a b
 Fig. 2. T1-weighted magnetic resonance superimposition of the data presented in  table 2 . Comparisons be-
tween  18 F-FDG uptake in LOAD patients (n = 61) and that in EOAD patients (n = 23) showing a reduction in 
cortical glucose consumption in the left precuneus ( a , sagittal view) and in the left supramarginal gyrus ( b , 
axial view) in the latter group.   
 Table 3. Numerical results of SPM comparisons between 18F-FDG uptake in O65 AD patients (n = 61) and U65 AD patients 
(n = 23)
Analysis Cluster level  Voxel level
cluster p 
(FWE-corr)
cluster 
p (FDR-corr)
cluster 
extent
cortical 
region
Z score of 
maximum
T alairach 
coordinates
cortical region BA
O65 – U65 0.000 0.000 14932 L parietal 4.83 –2, –72, 46 Precuneus 7
L parietal 4.50 –2, –52, 30 Precuneus 31
L parietal 4.38 –60, –48, 34 Supramarginal
gyrus
40
U65 – O65 – – – – – – – –
 In the ‘cluster level’ section on the left, the number of voxels, the corrected p value of significance and the cortical region 
where the voxel is found are all reported for each significant cluster. In the ‘voxel level’ section, all of the coordinates of the 
correlation sites (with the Z score of the maximum correlation point), the corresponding cortical region and the BA are reported 
for each significant cluster. In case the maximum correlation is achieved outside the gray matter, the nearest gray matter (within 
a range of 5 mm) is indicated with the corresponding BA. FWE = Familywise error; FDR = false discovery rate.
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 CG Subjects (O65 vs. U65 and vice versa) 
 As compared to O65 subjects, U65 subjects did not show any area of decreased glucose 
consumption. As compared to U65 subjects, O65 subjects showed a reduced glucose 
consumption in the right cingulate cortex (BA24 and BA32). Detailed results are provided in 
 table 4 and  figure 3 .
 AD versus CG Subjects  
 As compared to CG subjects with a similar age, LOAD patients showed a significant 
reduction in glucose consumption in a wide portion of the right parietal lobe (BA7) and the 
left temporal lobe (BA20 and BA37). No significant differences were obtained when subtracting 
the O65 LOAD subjects from the LOAD group. As compared to CG subjects with a similar age, 
the EOAD group showed a significant reduction in glucose consumption in a wide portion of 
the right parietal lobe (BA7). No significant differences were obtained when subtracting the 
U65 from the EOAD subjects. Detailed results are provided in  tables 5 and  6 .
 Discussion 
 In the early phases, AD is mainly characterized by memory dysfunction, except for cases 
with early onset that present with an atypical neuropsychological profile. Most of the available 
literature focused on these cases with a typical presentation, describing their neuropsycho-
 Fig. 3. T1-weighted magnetic res-
onance superimposition of the CG 
data presented in  table 2 . Com-
parisons between  18 F-FDG uptake 
in O65 CG subjects (n = 36) and 
that in U65 CG subjects (n = 22) 
showing a reduction in cortical 
glucose consumption in the left 
anterior cingulate cortex in O65 
as compared to U65 subjects.  
 Table 4. Numerical results of SPM comparisons between 18F-FDG uptake in O65 CG subjects (n = 36) and U65 CG subjects 
(n = 22)
Analysis Cluster level Voxel level
cluster 
p (FWE-corr)
cluster 
p (FDR-corr)
cluster 
extent
cortical 
region
Z score of 
maximum
Talairach 
coordinates
cortical region BA
U65 – O65 0.000 0.000 2683 R limbic 5.84 2, 30, 22 Anterior cingulate 24
R limbic 4.50 –2, –52, 30 Cingulate gyrus 32
O65 – U65 – – – – – – – –
In the ‘cluster level’ section on the left, the number of voxels, the corrected p value of significance and the cortical region where the 
voxel is found are all reported for each significant cluster. In the ‘voxel level’ section, all of the coordinates of the correlation sites (with 
the Z score of the maximum correlation point), the corresponding cortical region and the BA are reported for each significant cluster. 
In the case that the maximum correlation is achieved outside the gray matter, the nearest gray matter (within a range of 5 mm) is indi-
cated with the corresponding BA. FWE = Familywise error; FDR = false discovery rate.
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logical, biomarker (CSF/PET) and MRI profiles. Here, we studied CSF and  18 F-FDG PET differ-
ences between the EOAD and LOAD groups with a typical amnestic presentation. Our results 
show that EOAD patients with an amnestic presentation show features comparable to those 
observed in the EOAD group with an atypical presentation, and, moreover, confirm the finding 
that EOAD CSF and  18 F-FDG PET features differ from LOAD. CSF biomarker analysis showed 
comparable levels of Aβ 1–42 and Tau (both total and phosphorylated) between EOAD and 
LOAD, although t-Tau levels showed higher levels in the EOAD group. These findings are in 
line with the previous literature  [27–29] and indicate that in younger individuals the neuro-
degenerative process remains dependent on Aβ pathology, shows a stronger intensity of 
neurodegeneration and likely progresses more rapidly than what is observed in LOAD indi-
viduals. Although the t-Tau levels in our group of EOAD patients remained higher than those 
 Table 5. Numerical results of SPM comparisons between 18F-FDG uptake in O65 AD patients (n = 61) and O65 CG subjects 
(n = 36)
Analysis Cluster level Voxel level
cluster 
p (FWE-corr)
cluster 
p (FDR-corr)
cluster 
extent
cortical 
region
Z score of 
maximum
Talairach 
coordinates
cortical region BA
O65 CG – O65 AD 0.000 0.000 12182 R parietal 7.22 12, –58, 36 Precuneus 7
R parietal 6.95 10, –52, 36 Precuneus 7
R parietal 6.68 4, –72, 36 Precuneus 7
0.012 0.009 14460 L temporal 5.58 –60, –36, –20 Inferior temporal 
gyrus
20
L temporal 3.24 –44, –56, –12 Fusiform gyrus 37
O65 AD – O65 CG – – – – – – – –
In the ‘cluster level’ section on the left, the number of voxels, the corrected p value of significance and the cortical region 
where the voxel is found are all reported for each significant cluster. In the ‘voxel level’ section, all of the coordinates of the 
correlation sites (with the Z score of the maximum correlation point), the corresponding cortical region and the BA are reported 
for each significant cluster. In case the maximum correlation is achieved outside the gray matter, the nearest gray matter (within 
a range of 5 mm) is indicated with the corresponding BA. FWE = Familywise error; FDR = false discovery rate.
 Table 6. Numerical results of SPM comparisons between 18F-FDG uptake in U65 AD patients (n = 23) and U65 CG subjects 
(n = 22)
Analysis Cluster level Voxel level
cluster 
p (FWE-corr)
cluster 
p (FDR-corr)
cluster 
extent
cortical 
region
Z score of 
maximum
Talairach 
coordinates
cortical 
region
BA
U65 CG – U65 AD 0.000 0.000 22089 R parietal 7.93 42, –62, 50 Precuneus 7
R parietal 7.75 42, –76, 42 Precuneus 19
U65 AD – U65 CG – – – – – – – –
In the ‘cluster level’ section on the left, the number of voxels, the corrected p value of significance and the cortical region 
where the voxel is found are all reported for each significant cluster. In the ‘voxel level’ section, all of the coordinates of the 
correlation sites (with the Z score of the maximum correlation point), the corresponding cortical region and the BA are reported 
for each significant cluster. In case the maximum correlation is achieved outside the gray matter, the nearest gray matter (within 
a range of 5 mm) is indicated with the corresponding BA. FWE = Familywise error; FDR = false discovery rate.
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found in the LOAD group, the differences did not reach significance, and, unfortunately, we 
are unable to help solving controversies on CSF differences between EOAD and LOAD  [27, 28, 
30] .  18 F-FDG  PET showed unexpectedly that typical EOAD presents an asymmetric pattern 
with hypometabolism in the left precuneus (BA7 and BA31) and supramarginal gyrus (BA40), 
as observed in the description of atypical cases, and with a localization that differs from LOAD. 
Such findings led us to suppose that the asymmetric localization observed in  18 F-FDG  PET is 
not dependent on the clinical presentation of the cases (typical/atypical), but rather on a 
regional vulnerability of associative areas of the brain, whose involvement might determine 
the slower/faster evolution observed in AD cases  [30, 31] . 
 The precuneus is a medial parietal lobe region with associative functions. It is highly 
connected to other cortical regions and also receives innervations from subcortical nuclei like 
the cholinergic basal forebrain  [32] . It has also been shown that the precuneus together with 
other cortical regions (i.e. medial prefrontal and posterior cingulate cortices, hippocampus) 
act as a hub region of the rest-active default mode network (DMN). This consists of a specific 
set of brain areas that decrease activity during the performance of a wide range of tasks, and 
that are active during the period of rest  [33] . The different DMN structures are highly inter-
connected cortical processing networks involved in tasks like memory, vision, hearing and 
emotions. Early changes of the DMN were recently described and implicated in the patho-
genesis of AD symptoms, where reduced activation of the prefrontal and cingulate cortices 
and the precuneus appear as reliable markers from the early phases of the disease  [34] . Inter-
estingly, reduced activity of the precuneus has been associated with AD variants, with nonam-
nestic presentation, while in this work we show that also in the amnestic presentation of 
EOAD patients, the precuneus presents with reduced metabolic activity. Such a finding, on the 
one hand, strengthens the concept of heterogeneity of presentations in AD, but on the other 
hand, it indicates that the onset and evolution of the neurodegeneration of AD could be 
dependent specifically on the site or regional cortical vulnerability or on the specific 
involvement of DMN nodes. Indeed, both the LOAD and EOAD groups in our study showed 
focal hypometabolism, although in different cortical regions (left precuneus for the EOAD 
group and right cingulate cortex for the LOAD group, both considered nodes of the DMN). 
Apparently, each node has its specific vulnerability and, therefore, shows a different age at 
onset as well as evolution. Of note, such differences in cortical vulnerability could also be 
independent of the normal aging process. Aging induces changes in the DMN and may have 
further deleterious effects on cortical connectivity destructuration. Thus, precocious cortical 
deafferentation, due to abnormal Aβ metabolism or Tau hyperphosphorylation  [35] , would 
induce rapid cortical disorganization in regions less involved in memory functions, like the 
precuneus, and determine the intensity of degeneration as well as the evolution rate (slow/
fast) of cognitive deficits, besides a neuropsychological presentation  [34, 36, 37] . Such a 
notion would also help to solve the controversies about CSF biomarkers, showing that differ-
ences between the two groups reside in the intensity of neurodegeneration of cortical hubs. 
Of course this is a suggestive hypothesis, and studies of larger cohorts of patients are needed 
to deepen our knowledge. 
 In conclusion, we found that EOAD patients with a typical amnestic presentation show 
CSF abnormalities with low Aβ 1–42 and very high t-Tau levels, though not significantly different 
from LOAD patients, as well as precuneus hypometabolism. These features are similar to 
those described in the literature for cases with an atypical presentation, which confirms that 
EOAD represents a unique clinicopathologic entity. Finally, we suggest that EOAD should be 
considered as an expression of precocious cortical network hub disorganization. In addition, 
using CSF biomarkers as a covariate in the SPM analyses, we are also able to evaluate the age 
factor independently of CSF biomarkers and main cognitive parameters (see the Materials 
and Methods section). This type of analysis allows demonstrating that ‘age at onset of AD’ is 
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a factor related to a peculiar metabolic phenotype of the disease and suggests that in EOAD 
patients the cortical metabolism in the left precuneus and supramarginal gyrus should be 
considered carefully in the evaluation of PET images independently of the expected results 
based on other factors such as CSF biomarkers. In a recently published study performed on a 
large cohort of AD subjects, it has been shown that an increased amyloid burden in the brain 
is related to nonselective cortical dysfunction in AD (with a great reduction of brain glucose 
metabolism being detectable in those patients with low Aβ 1–42 levels in CSF)  [38] . A more 
selective pattern that mainly involves the cingulate cortex was related to high t-Tau and 
p-Tau values in CSF. All these areas were not detectable in the comparison between EOAD 
and LOAD, as shown in  table 2 . As a last aspect, our study shows an age-related reduction in 
glucose consumption in the right anterior cingulate cortex in the CG’s BA24 and BA32 ( table 3 ). 
Cerebral glucose metabolism is mainly related to glucose consumption in neural cells due to 
synaptic activity; hence, the reduced glucose consumption observed is consistent with an age-
related, reduced function of BA24 and BA32. Our findings are in agreement with several 
investigations reporting an age-related reduction in synaptic density or in synaptic count in 
the human cerebral cortex  [39, 40] , and such reductions have most consistently been reported 
in the frontal neocortex  [41] . A reduced cortical activity in BA24 and BA32 in O65 as compared 
to U65 subjects could be explained with an age-related impairment in the working memory 
process, with this structure being actively involved during memory tasks  [42] . 
 A significant limitation of our study is the lack of a dedicated neuropsychological evalu-
ation of this domain in the CG; it will be necessary for future studies to include longitudinal 
assessments of neuropsychological performance in order to investigate an impairment of 
those areas where a hypometabolism has been found in elderly as compared to young healthy 
subjects.
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